Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide is designed to reduce hunger, yet some people find themselves feeling more hungry at certain points during treatment — particularly when switching doses or after a period of eating very little. That experience is real, and it makes sense to understand why. Semaglutide (the active ingredient in Wegovy) works by mimicking the GLP-1 hormone, which slows gastric emptying and signals the brain that you've had enough to eat. Most people notice a meaningful drop in appetite, especially once they reach a higher maintenance dose. But the picture isn't always that straightforward, and a prescriber reviewing your progress is the right person to help you make sense of it. These are prescription-only medicines that require clinical assessment before treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people start semaglutide expecting hunger to simply disappear, and for many it largely does, particularly once the dose climbs toward the 1.7mg or 2.4mg maintenance range. The STEP 1 trial, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at 2.4mg, which reflects genuinely reduced calorie intake over a sustained period. That doesn't happen without appetite suppression doing real work.
But appetite isn't a simple dial. GLP-1 receptor agonists slow how quickly food leaves the stomach and send satiety signals to the brain, but the brain also adjusts to new inputs over time. Some people notice their hunger beginning to creep back in the days before their next weekly injection, particularly at lower doses early in treatment. Others find that a period of eating very little has left their metabolism sensitive to any gap, skipping breakfast on a Saturday and feeling genuinely hungry by midmorning is not unusual, even on treatment.
If you're wondering whether semaglutide can actually make you hungry, the answer depends on factors like dose, timing within the weekly cycle, and what you're eating.
One pattern prescribers see fairly often: a patient is eating far less overall, which is the intended effect, but the food they are eating is low in protein and fibre. Semaglutide suppresses appetite, it doesn't guarantee the body gets enough of what it needs. If most of your reduced intake is refined carbohydrate and very little is protein, hunger signals can return faster than expected, because protein and fibre both independently prolong satiety through separate mechanisms.
There is also the matter of muscle. When the body is in a significant calorie deficit, it may draw on lean tissue as well as fat. The question of muscle loss on semaglutide is one our prescribers are asked about regularly, adequate protein intake and some resistance activity are the main practical levers available to people in treatment. Both also help with hunger management in their own right.
The NHS medicines page for semaglutide recommends combining treatment with a reduced-calorie diet and increased activity, and that framing matters: the medicine supports the process, but diet quality shapes how comfortable and sustainable that process feels. A few practical notes on what to eat while on Wegovy can make a real difference to how hunger behaves week to week.
The semaglutide titration schedule starts at 0.25mg and steps up roughly every four weeks, reaching a maintenance dose of 2.4mg (or, for eligible patients assessed by their prescriber, the newer 7.2mg dose). Each step up is intended to improve the medicine's effect on weight, but the period immediately after a dose change is one where the body is adjusting. For some people, that adjustment period is accompanied by gastrointestinal symptoms (nausea, fullness, discomfort) that naturally suppress eating. Once those symptoms settle, appetite can feel comparatively stronger again, even though the dose has increased.
This can catch people off guard. The transition between doses is genuinely the point at which hunger patterns are most variable. It usually settles. But if you find hunger is consistently stronger than it was at your previous dose, or if it persists well beyond a couple of weeks at a new level, that is exactly the kind of observation worth raising with your prescriber. Treatment is reviewed regularly for this reason, no single experience is universal, and adjustments are there to be made.
If what you're experiencing sounds less like fluctuation and more like a persistent pattern, our page on whether Wegovy can make you more hungry explores why this happens and what tends to drive it, including the questions worth putting to your clinical team. For situations that feel more established over time, feeling more hungry on Wegovy covers that specific situation in more detail.
Not every bout of hunger during semaglutide treatment needs an intervention. The question worth asking yourself is whether the hunger is new, persistent, and getting in the way of treatment, or whether it is the ordinary variation that comes with any medicine that works through hormonal signals rather than willpower suppression.
A useful prompt: keep a rough note for a week of when hunger peaks (time of day, day within the weekly injection cycle, what you last ate). Many people find a clear pattern, pre-injection day hunger, or late-afternoon hunger on days with a light lunch. That information gives a prescriber something concrete to work with at your next review.
The broader Wegovy treatment page covers how the medicine is structured and what clinical assessment involves. If you haven't yet started treatment and are weighing up whether it's right for you, the starting point is always a clinical conversation. Our prescribers at nume review every consultation personally, a real clinician reads your answers the same day and considers your full picture before any prescription is issued. You can start your free consultation when you're ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.